Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JPN1: A Confirmatory, Bridging, Double-Blind, Randomized, Controlled Trial in Japan Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence

Next Previous
Trial Profile

JPN1: A Confirmatory, Bridging, Double-Blind, Randomized, Controlled Trial in Japan Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iltamiocel (Primary)
  • Indications Urinary incontinence; Urinary-Stress-Incontinence
  • Focus Registrational; Therapeutic Use
  • Acronyms JPN1
  • Sponsors Cook MyoSite

Most Recent Events

  • 27 Aug 2024 Planned End Date changed from 1 Jun 2026 to 1 Jun 2027.
  • 27 Aug 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2026.
  • 27 Aug 2024 Planned initiation date changed from 1 Jun 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top